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ABSTRACT: An alternative approach toward the simple and robust synthesis of highly substituted peptidic thiazole derivatives
using Ugi-multicomponent reaction (U-MCR) is described. Thus, we introduced the enantiopure (R)-2-methyl-2-isocyano-3-
(tritylthio)propanoate as a novel class of isocyanide in MCR. This bifunctional isocyanide was found to undergo mild
cyclodehydration to aﬀord thiazole containing peptidomimetics in a short synthetic sequence. Several examples of bis-
heterocyclic rings were also synthesized through the proper choice of the aldehyde component in the U-4CR. The method opens
a wide range of applications toward the synthesis of nonribosomal natural products and other bioactive compounds.
■ INTRODUCTION
Cysteine (Cys, C) possessing peptides and proteins have
attracted widespread attention in medicinal chemistry as well as
chemical biology.1,2 It has been the most prominent target in
protein chemical synthesis3 and post-translational modiﬁca-
tions.4 One such modiﬁcation involves the biosynthetic
incorporation of thiazole onto the growing peptide through
enzymatic cyclization (Figure 1).5 The thiazole moiety has been
commonly found in a variety of natural products with
associated interesting biological activities.6,7 Plantazolicin is a
structurally impressive natural product containing multiple
oxazole and thiazole moieties in which three and four
heterocyclic rings are connected in a consecutive fashion.8 A
large number of synthetic drugs also contain a thiazole ring as
an active part in the molecule.9 Due to the broad spectrum of
pharmacological activities of 1,3-azoles, numerous methods for
their preparation have been described.10 Commonly available
synthetic methods mostly involve conventional peptide syn-
thesis bearing Cys/Ser/Thr amides followed by cylcodehydra-
tion and oxidation.11 However, the classical peptide synthesis is
sequential, time-consuming, and costly. Alternatively, the Ugi
multicomponent reaction (U-MCR) is an alternative approach
for the synthesis of short peptide sequences.12 It produces α-
amino-amides from isocyanides which allows for an easy and
simple method for the synthesis of libraries of small molecules,
peptides, peptidomimetics, and macrocycles.13 Additionally,
postcondensation modiﬁcation of isocyanide-based MCRs
allow for a simple and fast entry to medicinal chemistry
applications.14,15
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Figure 1. Biosynthesis of 1,3-azoles from Cys and Ser peptides.
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Focusing on the synthesis of thiazole derivatives through U-
MCR, we have previously developed a one-pot thiazole
synthesis through the Ugi reaction of thioacids and Schöllkopf
isocyanide (Figure 2A, route 1).16 The reaction was used in the
total synthesis of tubulysin derivatives.17 Similarly, the
Kazmaier group employed a two-step synthesis involving U-
MCR of thioacid and isocyanodimethylacetal, and the resulting
endothiopeptidic derivatives were cyclized to yield terminal
thiazole peptide analogues (Figure 2A, route 2).18Although, the
methods oﬀer a variety of advantages but still they deserve
improvement due to the limited availability of thioacids and the
rather low yields due to the air sensitive nature of the thioacids.
To overcome these issues, we were interested in an alternative
MCR strategy for the synthesis of 1,3-azole derivatives. In this
context, synthesis of isocyanide derived from cysteine amino
acid would be an ideal choice. Moreover, dipeptide isocyanide
bearing cysteine derivatives with an S-ethyl carbamate
protecting group have been recently described for the synthesis
of polyisocyanides.19 In another report, (R)-methyl 3-
(benzythio)-2-isocyanopropanoate was described for the syn-
thesis of corresponding isoselenocyanate.20 However, benzyl
protection for thiol is not promising for many post-
modiﬁcations on sulfur. Very recently, we have synthesized
the stable and enantiomerically pure chiral isocyanide derived
from S-trityl protected cysteine and employed it for the
preparation of disulﬁde bridged macrocycles.21 Herein we
describe another important application of isocyanide 4 in U-
MCR to access peptidic thiazole derivatives in short (Figure
2B).
■ RESULTS AND DISCUSSION
We synthesized isocyanide 4 from readily available Cys(Trt)-
OH 1 according to Scheme 1. The esteriﬁcation of 1 with
thionyl chloride yielded 2 in quantitative yield. The latter was
subjected to formylation with methylformate to aﬀord formyl
protected Cys(Trt)-OMe 3 in 95% yield. Next, we examined
the enantiopure preparation of isocyanide 4. Commonly
employed dehydrating conditions, such as POCl3/TEA,
POCl3/NMM, diphosgene/NMM at −78 °C resulted in
considerable racemization and also aﬀords low yields.22,14b
Burgess reagent23 and phosgene derivatives have been
commonly employed for the epimerization-free synthesis of
amino acid isocyanides.24 We carried out the dehydration of 3
in the presence of triphosgene (0.35 equiv) and NMM (2.0
equiv) at −78 °C for 3 h and in fact isocyanide 4 was obtained
in 85% yield and high enantiopurity as shown by chiral HPLC
(SI).25 The synthesis of 4 has also been performed on a 30 g
scale.
To demonstrate the usefulness of the novel isocyanide 4, we
tested its competency in peptide synthesis involving U-MCR.
The most straightforward approach would involve ammonia as
an amine component. However, the Ugi reaction using
ammonia is often described as complex and low yielding, or
no product formation is observed at all.26 To overcome these
issues, cleavable amine components or ammonium salts of
carboxylic acid have been developed.27 However, cleavable
amine or aldehyde components require additional steps, and
racemization is possible.28 In principle, ammonium salts of
carboxylates could be ideal components in the U-MCR due to
their general and simple preparation while maintaining a
neutral pH during the Ugi reactions thus avoiding racemization
during the peptide synthesis.29 Therefore, we have synthesized
ammonium salt of carboxylates derived from N-protected
amino acids (1.0 equiv) by the treatment of ammonium
bicarbonate in a mixture of CH3CN:H2O. The ammonium salts
were easy to isolate by ﬁltration. In a general Ugi reaction the
aldehyde component was added to the ammonium salt of
carboxylate in triﬂuoroethanol (TFE, 0.1 M) at 0 °C. After 15
min isocyanide 4 was added and allowed to stir at r.t. for 24 h
(Table 1). Aldehyde such as paraformaldehyde and isovaler-
aldehyde produced the Ugi adducts 5a−c in moderate yields.
Next, with the aim to access oxazoles, we focused on the
incorporation of serine side chains into peptides using
glycolaldehyde dimer (Table 1, entries 5d−f).
In these cases, the Ugi products were obtained in moderate
yields without detection of any byproducts such as Passerini or
Ugi-5C-3CR products as previously observed.30 The synthesis
of selenopeptidic derivatives through U-MCR reaction have
been well described.31 However, similar incorporation of sulfur
is less common through U-MCR, for example, spiro derivatives
of thiazolines were employed as components in U-MCR for the
Figure 2. (a) Previous works on thiazole synthesis using Ugi
multicomponent reaction and (b) this work.
Scheme 1. Synthesis of Chiral Cys(Trt)-Isocyano Methyl
Ester 4a
aconditions: (a) SOCl2, MeOH, reﬂux, 6h;(b) Methyl formate, reﬂux,
24 h; (c) Triphosgene, NMM, −78 °C, 3 h.
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assembly of constrained analogues of peptides.32 In an eﬀort to
introduce Cys moieties into glutathione derivatives, benzylthio
aldehdyes and ketones were used in the Ugi reaction.33 The
benzyl protecting group for thiol, however, is not compatible
for a straightforward postmodiﬁcation strategy. The simple and
scalable preparation of trityl protected mercaptoacetaldehyde as
a component in U-4CR is therefore a viable alternative to other
procedures.34 Interestingly, trityl protected mercaptoacetalde-
hyde reacted with the ammonium salts of N-protected acids
and isocyanide 4 at r.t. The reaction indeed worked well and
the respective Ugi products were obtained in moderate yields
(Table 1, entries 5g−i). These examples demonstrate that
sequential Cys(Trt) derivatives can be incorporated into the
peptide backbone through the U-MCR. To demonstrate the
general utility of the isocyanide 4 in the classical U-4CR, simple
primary amines, acids, and aldehydes were also employed. The
resulting N-alkylated Ugi products were obtained in excellent
yields (Table 1, entries 5j−l). The diastereoselectivity of the
Ugi products varied from 1:0.5 to 1:0.8. Compounds 5a and 5b
were obtained as single crystals, and analysis conﬁrmed their
structures (Figure 3). As shown in Table 1, the yields of Ugi
products 5a−5i are low when compare to the Ugi products 5j−
5l. The moderate yields for 5a−5i is due to slow reactivity of
the aldehydes with ammonium salt of carboxylates as evidenced
by the LC-MS analysis of the crude reaction mixtures which
showed only desired product and unreacted staring materials.
The retention of the optical purity of the isocyanide or the
carboxylic acid was accessed using model Ugi products 5m and
5n (Figure 4). The excellent enantioselectivities observed in
Ugi products 5a and 5m revealed that retention of chirality is
maintained in the isocyanide part. An additional set of Ugi
products 5a and 5n also showed that negligible epimerization
was observed even at the N-protected amino acids. No
racemization observed here, we speculate, is due to the neutral
conditions in the Ugi reaction. This is also supported by the
work of others.28d
Having Cys(Trt) containing Ugi products at hand, we next
elaborated the cyclodehydration toward thiazoles. We envi-
sioned a cascade cyclization of Ser/Cys(Trt) or Cys(Trt)/
Cys(Trt) amides fallowed by oxidation of resulting azolines to
azoles in one-pot to avoid tedious isolations and puriﬁcations of
intermediates. Activated MnO2 has been commonly used
oxidant for the conversion of azolines to azoles, and it is highly
compatible for many organic solvents. We speculated that
direct treatment of MnO2 after the cyclodehydration could
access to thiaozles in one-pot. Consequently, various known
cyclodehydrating fallowed by MnO2 oxidation procedures were
examined by using 5d as a model substrate (Table 2).
Literature reported reagents such as TiCl4 (Table 2, entries a,
b),35 diethylaminosulfur triﬂuoride (DAST) (Table 2, entries c,
d),36 and tosyl chloride (Ts-Cl) (Table 2, entries e, f)37 were
tested under various conditions from equimolar amounts to
large excess.
All these reagents aﬀorded complex product mixtures and
often in low yields. Finally, we employed Tf2O (3.0 equiv)/
PPh3O (6 equiv) at −78 °C (Table 2, entry g) and 6d was
obtained in 18% yield.38 The reaction was carried out at −20
°C (Table 2, entry h) resulting in 28% yield of 6d. Further
optimization increasing the amount of reagents and time did
not give improved results. Encouragingly, changing the additive
Table 1. Synthesis of Ugi Products 5 Using Isocyanide 4a
aIsolated yields are given; diastereomeric ratios are given according to
1H NMR analysis; enantiomeric excess determined by chiral SFC-
HPLC
Figure 3. ORTEP pictures of Ugi products 5a and 5b.
Figure 4. Racemization test for U-4CR. a(D)-Enantiomer of the
isocyanide 4 is used in U-4CR. bFmoc-(D)-Val-OH is used as acid
component; isolated yields are given; enantiomeric excess determined
by chiral SFC-HPLC
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to Ph2SO (6 equiv) and using pyridine (10 equiv) as base in the
presence of Tf2O at −78 °C aﬀorded 62% of 6d after MnO2
oxidation (Table 2, entry (i).39 As shown in Table 3, the
optimized conditions worked well for bis- as well as
monocyclodehydration of Cys(Trt)-amides (Table 3, 6a−6l).
In order to examine the racemization of the intermediate
thiazolines, two peptide thiazolines 7a and 7b were isolated in
moderate yield and were obtained in good enantioselectivity,
indicating low epimerization (Figure 5).
■ CONCLUSIONS
In summary, we have introduced the cysteine-derived chiral
isocyanide 4 as a versatile component for the short synthesis of
thiazole and bis-oxazole/thiazole derivatives via Ugi-MCR and
subsequent cyclodehydration strategy. We believe the method-
ology will prove for the formation of oxazole and thiazole
fragments in natural product synthesis and their unnatural
derivatives as well as in the synthesis of heterocyclic libraries to
enrich screening decks, for example the European Lead
Factory.40 Additionally, the described novel isocyanide has
wide synthetic applications in multicomponent reactions
beyond thiazole formation, as we will communicate shortly.
■ EXPERIMENTAL SECTION
General Methods. All N-protected amino acids, reagents, and
solvents were purchased from Sigma-Aldrich. The enantiomers of the
Cys(Trt)-OH were purchased from abcr GmbH company and were
used as-received. All reaction mixtures were stirred magnetically and
were monitored by thin-layer chromatography using silica gel
precoated glass plates, which were visualized with UV light and
then, developed using iodine. Flash chromatography was performed on
a Teledyne ISCO Combiﬂash Rf, using RediSep Rf normal−phase
silica ﬂash columns (Silica Gel 60 Å, 230−400 mesh). Cyclo-
dehydration was carried out under nitrogen atmosphere. Nuclear
magnetic resonance spectra were recorded on a Bruker Avance 500
spectrometer {1H NMR (500 MHz), 13C NMR (125 MHz)).
Chemical shifts for 1H NMR were reported as δ values and coupling
constants were in hertz (Hz). 1H and 13C NMR values are given for a
major diastereomeric Ugi product. Mass spectra were measured on a
Waters Investigator Supercritical Fluid Chromatograph with a 3100
MS Detector (ESI) using a solvent system of methanol and CO2 on
either a Viridis 2-ethylpyridine column (4.6 × 250 mm2, 5 μm particle
size) or a Viridis silica gel column (4.6 × 250 mm2, 5 μm particle size)
and reported as (m/z). The speciﬁcations of chiral SFC-HPLC details
are given on respective spectra. Optical rotations were measured using
a 1 mL cell with a 10 mm path length on an P-2000 JASCO digital
polarimeter.
Methyl S-trityl-L-cysteinate, 2. This compound was synthesized
according to the procedure of Graham et al., and the analytical data
were compared.41
To a stirred solution of S-trityl-L-cysteine (1.0 g, 2.76 mmol) in 50
mL of methanol at 0 °C was added thionyl chloride (1.50 mL, 0.206
mmol) in a dropwise fashion. The solution was allowed to warm to r.t.
and then reﬂuxed at 80 °C for 5 h. The solvent was removed under
reduced pressure, and the crude product was extracted with ethyl
acetate and washed with saturated sodium bicarbonate several times.
The organic layer was dried over anhydrous magnesium sulfate,
ﬁltered, and concentrated to give ester 2 as a pale yellow gum. Yield =
85% (0.865 g), yellow gum, Rf 0.41 (PE/EtOAc, 1:1), [α]D
20 = +31.5
(C1, CHCl3).
1H NMR (500 MHz, CDCl3) δ 7.47−7.14 (m, 15H),
6.73−6.78 (br, m, 2H), 3.62 (s, 3H), 3.20 (m, 1H), 2.58 (dd, J = 12.4,
4.9 Hz, 1H), 2.47 (dd, J = 12.5, 7.7 Hz, 1H). 13C NMR (126 MHz,
CDCl3) δ 174.1, 144.4, 129.7, 129.5, 128.0, 127.9, 127.7, 126.8, 126.7,
66.8, 53.7, 52.1, 36.8. MS (ESI) m/z: [M + Na]+ Calcd. for
C23H23NO2SNa 400.13; Found 400.10.
Methyl N-Formyl-S-trityl-L-cysteinate, 3. Amine 2 (1.0 g, 2.65
mmol) was dissolved in methyl formate (10 mL, solvent), and the
solution was allowed to reﬂux at 60 °C until TLC showed complete
consumption of the starting material (usually 24 h). The solvent was
evaporated, and the product was puriﬁed through column chromatog-
raphy to yield formyl ester 3 as a white solid. Yield = 95% (1.03 g),
white solid, mp: 132−133 °C, Rf 0.50 (PE/EtOAc, 1:1), [α]D20 =
+19.1 (C1, CHCl3).
1H NMR (500 MHz, CDCl3) δ 7.95 (s, 1H),
7.50−7.11 (m, 15H), 6.14 (d, J = 8.1 Hz, 1H), 4.64 (dt, J = 8.2, 5.2 Hz,
1H), 3.68 (s, 3H), 2.77 (dd, J = 12.7, 5.8 Hz, 1H), 2.69 (dd, J = 12.9,
6.5 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 170.3, 160.4, 144.1,
129.4, 128.0, 128.0, 126.9, 126.8, 67.0, 52.6, 49.7, 33.5. HRMS (ESI-
TOF) m/z: [M + H]+ Calcd. for C24H24NO3S 406.1471; Found
406.1477.
Methyl (R)-2-Isocyano-3-(tritylthio)propanoate, 4. To a solution
of N-formyl Cys(Trt)-methyl ester 3 (30.0 g, 74.0 mmol) in CH2Cl2
(150.0 mL) at −78 °C, N-methylmorpholine (2.0 eq 16.5 mL) was
added. After 5 min triphosgene (7.6 g, 0.35 equiv) in CH2Cl2 (50.0
mL) was added dropwise, and the reaction mixture was stirred for 3 h
at −78 o C (TLC analysis). Saturated NaHCO3 solution (10 mL) was
added at same temperature and allowed to warm to r.t. The reaction
mixture was extracted with CH2Cl2, the organic extracts were
separated, dried over anhydrous Na2SO4, ﬁltered, and concentrated.
The solution was diluted with diethyl ether (10 mL) and stored at −15
°C for 5 h which resulted pure solid of isocyanide 4 which was
collected by ﬁltration. Yield = 85% (24.3 g), white solid, mp: 96−97
°C, Rf 0.42 (EtOAc/PE, 10:90), [α]D
20 = +32.8 (C1, CHCl3).
1H
NMR (500 MHz, CDCl3) δ 7.57−7.06 (m, 15H), 3.70 (s, 3H), 3.34
Table 2. Optimization Studies for the Synthesis of 6da
entry reagent conditions time (h) yield of 6d (%)
A TiCl4 (6 equiv) 0 °C to r.t. 48 10
B TiCl4 (6 equiv) r.t. 48
C DAST (5 equiv) −78 to 0 °C 24 12
D DAST (10 equiv) −78 to 0 °C 24 15
E Ts-Cl (10 equiv) 60 °C 24
F Ts-Cl (20 equiv) 60 °C 48
G Tf2O/PPh3O (3.0 eq./6equiv) −78 °C 8 18
H Tf2O/PPh3O (3.0 eq./6 equiv) −20 °C 8 28
I Tf2O/Ph2SO/Py (3.0 eq./6.0 eq / 10.0 equiv) −78 °C 5 62
aAll reactions were conducted at 1.0 mmol scale; time refers to the formation of thiazoline. Activated MnO2 (10 equiv) was added to the crude
thiazoline ﬂowed by reﬂuxed at 80 °C for 3 h in CHCl3; isolated yields are given.
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(dd, J = 7.7, 5.8, Hz, 1H), 2.89−2.63 (m, 2H). 13C NMR (126 MHz,
CDCl3) δ 165.6, 160.9, 143.9, 129.4, 129.2, 128.2, 128.0, 128.0, 127.9,
127.1, 67.5, 55.3, 53.4, 34.2. HRMS (ESI-TOF) m/z: [M + H]+ Calcd.
for C24H22NO2S 388.1365; Found 388.1363.
Methyl S-Trityl-R-cysteinate, 2b. This compound was synthesized
according to general procedure for the preparation of 2 by using S-
trityl-R-cysteine 1b (1.0 g, 2.76 mmol). Yield = 80% (0.830 g), yellow
gum; Rf 0.41 (PE/EtOAc, 1:1), [α]D
20 = −31.1 (C1, CHCl3). 1H
NMR (500 MHz, CDCl3) δ 7.50−7.18 (m, 15H), 6.72−6.75 (br, m,
2H) 3.61 (s, 3H), 3.24 (dd, J = 7.9, 4.8 Hz, 1H), 2.56 (dd, J = 12.5, 4.7
Hz, 1H), 2.48 (dd, J = 12.5, 7.8 Hz, 1H). 13C NMR (126 MHz,
CDCl3) δ 174.2, 144.5, 130.1, 129.6, 128.3, 128.0, 66.9, 53.8, 52.2,
36.9. MS (ESI) m/z: [M + Na]+ Calcd. for C23H23NO2SNa 400.13;
Found 400.04.
Methyl N-Formyl-S-trityl-R-cysteinate, 3b. This compound was
synthesized according to general procedure for the preparation of 3 by
using methyl S-trityl-R-cysteinate, 2b (1.0 g, 2.65 mmol). Yield = 78%
(0.837 mg), white solid, mp: 135−137 °C, Rf 0.50 (PE/EtOAc, 1:1),
[α]D
20 = −18.8 (C1, CHCl3). 1H NMR (500 MHz, CDCl3) δ 7.98 (s,
1H), 7.52−7.12 (m, 15H), 6.15 (d, J = 12.6 Hz, 1H), 4.69 (dt, J = 8.1,
5.2 Hz, 1H), 3.65 (s, 3H), 2.82 (dd, J = 12.7, 5.8 Hz, 1H), 2.67 (dd, J
= 12.7, 4.7 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 170.5, 160.6,
144.3, 129.6, 129.5, 128.2, 128.1, 127.1, 67.0, 52.8, 49.8, 33.7. HRMS
(ESI-TOF) m/z: [M + H]+ Calcd. for C24H24NO3S 406.1477; Found
406.1477.
Methyl (S)-2-Isocyano-3-(tritylthio)propanoate, 4b. This com-
pound was synthesized according to general procedure for the
preparation of 4 by using methyl N-formyl-S-trityl-R-cysteinate, 3b
(2.0 g, 5.0 mmol). Yield = 76% (20.9 g), white solid, mp: 101−103 °C,
Rf 0.42 (EtOAc/PE, 10:90), [α]D
20 = −32.9 (C1, CHCl3). 1H NMR
(500 MHz, CDCl3) δ 7.56−7.26 (m, 15H), 3.71 (s, 3H), 3.36 (dd, J =
7.9, 5.8 Hz, 1H), 2.89−2.60 (m, 2H). 13C NMR (126 MHz, CDCl3) δ
165.6, 160.9, 143.9, 130.7, 129.5, 128.3, 128.0, 128.0, 127.7, 127.3,
Table 3. List of Thiazole Derivatives Synthesizeda
aIsolated yields are given.
Figure 5. Thiazolines isolated for racemization test. aIsolated yields are
given; enatiomeric excess determined by chiral SFC-HPLC.
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127.2, 127.1, 67.6, 55.4, 53.4, 34.2. HRMS (ESI-TOF) m/z: [M + H]+
Calcd. for C24H22NO2S 388.1365; Found 388.1363.
Trityl Thioacetic Acid. This compound was synthesized according
to the procedure of Tam et al., and the analytical data were
compared.42
To a mixture of mercaptoacetic acid (3.48 mL, 50.0 mmol) and
triphenylmethanol (13.0 g, 50.0 mmol) in 50 mL of chloroform was
added triﬂuoroacetic acid (10 mL) in 5 min. After stirring at r.t. for 1
h, the volatiles were removed in vacuo. The crude product was puriﬁed
by recrystallization (CH2Cl2/Hexane; 1/2) to give trityl thioacetic
acid. Yield = 98% (16.3 g), white solid, mp: 159−161 °C, Rf 0.38
(EtOAc/PE/AcOH, 30:70:1.0). 1H NMR (500 MHz, CDCl3) δ 7.56−
7.15 (m, 15H), 3.06 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 175.5,
143.9, 129.5, 128.1, 127.9, 127.0, 67.3, 34.5. MS (ESI) m/z: [M +
Na]+ Calcd. for C21H18O2SNa 357.09; Found 357.21.
N-Methoxy-N-methyl-2-(tritylthio)acetamide. To a solution of
acid (20.0 mmol), PyBOP (1.1 equiv) and TEA (2.5 equiv) in CH2Cl2
(50 mL) was added N,O-dimethylhydroxylamine hydrochloride (1.2
equiv), and the solution was allowed to stir at r.t. overnight. The
solution was then diluted with excess CH2Cl2 and washed
consecutively with 1 M HCl solution (3 × 10 mL), saturated aq.
NaHCO3 (3 × 10 mL), and water (1 × 10 mL). The organic phase
was dried over MgSO4, ﬁltered and concentrated in vacuo. The residue
was puriﬁed by ﬂash chromatography on silica gel to aﬀord the desired
Weinreb amide. Yield = 95% (7.1 g), white solid, mp: 125−127 °C, Rf
0.32 (EtOAc/PE, 30:70). 1H NMR (500 MHz, CDCl3) δ 7.52−7.44
(m, 7H), 7.32−7.31 (m, 8H), 3.49 (s, 3H), 3.14 (s, 3H), 3.11 (s, 2H).
13C NMR (126 MHz, CDCl3) δ 172.0, 144.3, 129.6, 128.0, 127.8,
126.8, 66.9, 61.4, 33.7. MS (ESI) m/z: [M + Na]+ Calcd. for
C23H23NO2SNa 400.13; Found 400.25.
2-(Tritylthio)acetaldehyde. A stirred solution of Weinreb amide
(10.0 mmol) in dry THF (50 mL) was cooled to 0 °C. Lithium
aluminum hydride (LAH, 11.0 mmol) was added in portions and after
30 min 0.2 M KHSO4 (30 mL) was added. The organic compounds
were extracted with diethyl ether (3 × 30 mL). The combined organic
phases were washed with 1 M HCl (3 × 10 mL), brine (3 × 10 mL),
and dried (MgSO4). The solvent was evaporated under reduced
pressure and the crude colorless oil was used immediately in the Ugi
reaction (analysis was done only by TLC). Yield = 88% (2.7 g), pale
yellow oil, Rf 0.25 (EtOAc/PE, 10:90)
Preparation of Ammonium Salt of Carboxylate. Ammonium
bicarbonate (1.3 mmol) was added to a solution of N-protected amino
acid (1.0 mmol) in acetonitrile (10.0 mL) followed by dropwise
addition of water (1.0 mL) with rapid stirring. The ammonium salt of
carboxylate was precipitated out in 5 min. The stirring is continued for
another 5 min and the precipitate was ﬁltered, dried, and used for Ugi
reaction.
General Procedure for Ugi 4CR. Preparation of Ugi Products
5. Aldehyde component (1.3 mmol, 1.3 equiv) was added to a solution
of ammonium salt of carboxylate (1.2 equiv) in triﬂuoroethanol (10
mL) at 0 °C. After stirring for 30 min, isocyanide 4 (387 mg, 1.0
mmol, 1.0 equiv) was added. A small amount of THF (1.0 mL) was
added to get a homogeneous solution. The mixture was allowed to stir
r.t. for 24 h, and the solution was diluted with CH2Cl2 (30 mL) and
washed with 1 N KHSO4 and sat. NaHCO3 solution. The organic layer
was dried over Na2SO4, and the solvent was evaporated in vacuo. The
crude product was puriﬁed by ﬂash column chromatography to aﬀord
Ugi products.
“1N KHSO4 solution necessary to decolorize the reaction mixture
from dark yellow color to pale yellow and also helps to separate the
CH2Cl2 layer from the aqueous layer”.
Spectroscopic Data for Compounds 5a−l. Methyl N-(((9H-
Fluoren-9-yl)methoxy)carbonyl)-L-valylglycyl-S-trityl-L-cysteinate,
5a. Yield = 48% (0.360 g), white solid, mp: 132−133 °C, Rf 0.32
(EtOAc/PE, 50:50), [α]D
25 = +21.5 (C1, CHCl3).
1H NMR (500
MHz, CDCl3) δ 7.79−7.19 (m, 23H), 6.52 (br, s, 1H), 6.36 (d, J = 8.3
Hz, 1H), 5.38 (br, s, 1H), 4.58−4.50 (m, 1H), 4.43 (d, J = 7.5 Hz,
2H), 4.23 (t, J = 12.5 Hz, 1H), 4.04 (dd, J = 7.8, 15.6 Hz, 1H), 3.95 (s,
2H), 3.71 (s, 3H), 2.75 (dd, J = 12.1, 9.2 Hz, 1H), 2.69 (dd, J = 12.6,
6.3 Hz, 1H), 2.23−2.20 (m, 1H), 0.99 (d, J = 8.6 Hz, 3H), 0.88 (d, J =
6.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 172.0, 171.0, 170.1,
155.8, 144.0, 142.1, 140.7, 129.3, 127.8, 127.5, 126.9, 126.7, 124.9,
119.8, 66.9, 60.8, 56.5, 51.1, 47.0, 42.5, 33.3, 26.2, 18.9, 18.1. HRMS
(ESI-TOF) m/z: [M + H]+ Calcd. for C45H46N3O6S 756.3101; Found
756.3100.
Methyl N-((Benzyloxy)carbonyl)-L-alanylglycyl-S-trityl-L-cystei-
nate, 5b. Yield = 55% (0.351 g), white solid, mp: 115−116 °C, Rf
0.41 (EtOAc/PE, 50:50), [α]D
25 = +62.5 (C1, CHCl3).
1H NMR (500
MHz, CDCl3) δ 7.54−7.18 (m, 20H), 6.73 (br, s, 1H), 6.44 (br, s,
1H), 5.30 (d, J = 7.2 Hz, 1H), 5.15 (s, 2H), 4.51 (ddd, J = 7.9, 6.3, 4.7
Hz, 1H), 4.34−4.22 (m, 1H), 3.98 (s, 2H), 3.71 (s, 3H), 2.75 (dd, J =
12.7, 6.3 Hz, 1H), 2.65 (dd, J = 12.6, 4.7 Hz, 1H), 1.40 (d, J = 7.0 Hz,
3H). 13C NMR (126 MHz, CDCl3) δ 172.5, 170.7, 168.9, 155.3, 144.2,
136.0, 129.5, 128.6, 128.3, 128.2, 128.1, 127.0, 67.2, 64.1, 52.7, 51.3,
42.8, 28.3, 18.4. HRMS (ESI-TOF) m/z: [M + H]+ Calcd. for
C36H38N3O6S 640.2475; Found 640.2472.
Methyl N-((Benzyloxy)carbonyl)glycylleucyl-S-trityl-L-cysteinate,
5c. Yield = 60% (0.400 g), gummy solid, Rf 0.45 (EtOAc/PE,
50:50), [α]D
25 = +139.1 (C1, CHCl3).
1H NMR (500 MHz, CDCl3)
(major diastereomer) δ 7.48−7.17 (m, 20H), 6.55 (d, J = 8.5 Hz, 1H),
5.95 (d, J = 7.9 Hz, 1H), 5.42 (br, s, 1H), 5.13 (s, 2H), 4.64 (dt, J =
7.9, 5.2 Hz, 1H), 4.49−4.47 (m, 1H), 3.74 (s, 3H), 3.70 (s, 2H), 2.69−
2.60 (m, 2H), 1.82−1.75 (m, 2H), 1.53−1.49 (m, 1H), 0.93 (d, J =
7.9, Hz, 6H). 13C NMR (126 MHz, CDCl3) (major diastereomer) δ
171.5, 171.0, 168.9, 156.6, 144.3, 144.2, 136.1, 129.5, 128.6, 128.2,
128.1, 128.1, 128.1, 128.0, 128.0, 127.0, 127.0, 126.9, 126.9, 67.3, 67.0,
57.4, 57.1, 51.1, 44.6, 40.9, 29.1, 24.5, 23.1, 22.2. HRMS (ESI-TOF)
m/z: [M + H]+ Calcd. for C39H44N3O6S 682.2945; Found 682.2945.
Methyl N-((Benzyloxy)carbonyl)-L-phenylalanylseryl-S-trityl-L-cys-
teinate, 5d. Yield = 53% (0.39 g), white solid, mp: 129−132 °C, Rf
0.32 (EtOAc/PE, 70:30), [α]D
25 = +179.5 (C1, CHCl3).
1H NMR
(500 MHz, CDCl3) (major diastereomer) δ 7.44−7.37 (m, 6H),
7.36−7.12 (m, 19H), 7.10 (d, J = 6.6 Hz, 1H), 6.98−6.92 (m, br, 1H),
5.59 (d, J = 7.7 Hz, 1H), 5.03 (s, 2H), 4.51−4.31 (m, 3H), 3.90−3.80
(br, m, 1H), 3.68 (s, 3H), 3.67−3.59 (m, 1H), 3.45−3.30 (m, 2H),
3.15−2.95 (m, 2H), 2.70−2.60 (m, 2H). 13C NMR (126 MHz,
CDCl3) (major diastereomer) δ 171.6, 170.8, 169.9, 156.2, 144.5,
136.9, 136.2, 129.5, 129.3, 129.2, 128.7, 128.5, 128.2, 128.1, 128.0,
127.1, 127.0, 126.9, 67.7, 67.1, 62.7, 56.2, 54.0, 52.8, 51.8, 38.5, 33.1.
HRMS (ESI-TOF) m/z: [M + H]+ Calcd. for C43H44N3O7S 746.2894;
Found 746.2897.
Methyl N-((Benzyloxy)carbonyl)-L-alanylseryl-S-trityl-L-cysteinate,
5e. Yield = 60% (0.41 g), white solid, mp: 141−144 °C, Rf 0.35
(EtOAc/PE, 70:30), [α]D
25 = +75.6 (C1, CHCl3).
1H NMR (500
MHz, CDCl3) (major diastereomer) δ 7.43−7.14 (m, 20H), 7.11 (d, J
= 7.8 Hz, 1H), 6.78 (d, J = 7.8 Hz, 1H), 5.68 (d, J = 6.8 Hz, 1H), 5.13
(s, 2H), 5.05 (d, J = 11.8 Hz, 1H), 4.51−4.36 (m, 1H), 4.30−4.23 (m,
1H), 4.06 (Br, s, 1H), 3.69 (s, 3H), 3.35 (dd, J = 8.3, 5.6 Hz, 2H),
2.75−2.70 (m, 1H), 2.65−2.61 (m, 1H), 1.40 (d, J = 3.1 Hz, 3H). 13C
NMR (126 MHz, CDCl3) (major diastereomer) δ 170.8, 170.7, 156.2,
144.2, 136.2, 129.5, 128.5, 128.1, 128.0, 127.1, 126.8, 67.0, 62.4, 56.3,
54.5, 54.4, 52.6, 50.7, 26.3, 18.1. HRMS (ESI-TOF) m/z: [M + H]+
Calcd for C37H40N3O7S 670.2581; Found 670.2581.
Methyl N-((Benzyloxy)carbonyl)-L-valylseryl-S-trityl-L-cysteinate,
5f. Yield = 52% (0.36 g), white solid, mp: 125−127 °C, Rf 0.41
(EtOAc/PE, 70:30), [α]D
25 = +155.5 (C1, CHCl3).
1H NMR (500
MHz, CDCl3) (major diastereomer) δ 7.49−7.18 (m, 20H), 6.81 (d, J
= 7.8 Hz, 1H), 6.78 (d, J = 8.8 Hz, 1H), 5.46 (d, J = 8.2 Hz, 1H), 5.16
(s, 2H), 4.74−4.63 (m, 1H), 4.49−4.33 (m, 2H), 4.23−4.16 (m, 1H),
4.15−3.88 (m, 1H), 3.71 (s, 3H),3.24 (br, m, 1H), 2.87−2.76 (m,
1H), 2.68−2.57 (m, 1H), 2.16−2.03 (m, 1H), 0.92 (d, J = 11.8, Hz,
3H), 0.85 (d, J = 6.8, Hz, 3H). 13C NMR (126 MHz, CDCl3) (major
diastereomer) δ 174.6, 173.5, 170.4, 156.7, 144.2, 136.8, 129.5, 128.5,
128.1, 128.0, 127.8, 126.9, 68.1, 66.4, 64.2, 60.4, 56.8, 53.7, 51.7, 33.0,
27.3, 19.7, 17.9. HRMS (ESI-TOF) m/z: [M + H]+ Calcd. for
C39H44N3O7S 698.2894; Found 698.2894.
Methyl N-(N-(((Benzyloxy)carbonyl)-L-phenylalanyl)-S-tritylcys-
teinyl)-S-trityl-L-cysteinate, 5g. Yield = 45% (0.45 g), yellow gum,
Rf 0.38 (EtOAc/PE, 30:70), [α]D
25 = +155.9 (C1, CHCl3).
1H NMR
(500 MHz, CDCl3) (major diastereomer) δ 7.50−7.07 (m, 41H), 6.42
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(d, J = 18.2 Hz, 1H), 6.18 (d, J = 6.4 Hz, 1H), 5.04 (s, 2H), 4.38 (dt, J
= 7.5, 5.6 Hz, 1H), 4.20 (dd, J = 7.1, 2.7 Hz, 1H), 4.10−4.03 (m, 1H),
3.65 (s, 3H), 3.15−2.98 (m, 2H), 2.67−2.62 (m, 2H), 2.59−2.25 (m,
2H). 13C NMR (126 MHz, CDCl3) (major diastereomer) δ 172.4,
170.5, 155.7, 145.3, 144.2, 136.8, 136.4, 129.6, 129.5, 129.3, 128.9,
128.7, 128.5, 128.3, 128.2, 128.1, 128.0, 126.9, 126.8, 69.0, 67.0, 66.3,
65.8, 53.1, 52.0, 50.6, 38.3, 34.8, 28.7. HRMS (ESI-TOF) m/z: [M +
H]+ Calcd. for C62H58N3O6S2 1004.3761; Found 1004.3761.
Methyl N-(N-((((9H-Fluoren-9-yl)methoxy)carbonyl)-L-valyl)-S-tri-
tylcysteinyl)-S-trityl-L-cysteinate, 5h. Yield = 48% (0.50 g), pale
yellow solid, m.p: 113−116 °C, Rf 0.44 (EtOAc/PE, 30:70), [α]D25 =
−89.3 (C1, CHCl3). 1H NMR (500 MHz, CDCl3) (major
diastereomer) δ 7.95−7.00 (m, 38H), 6.72 (d, J = 7.6 Hz, 1H), 6.33
(d, J = 7.5 Hz, 1H), 5.59 (d, J = 8.5 Hz, 1H), 4.58−4.44 (m, 1H), 4.43
(t, J = 6.8 Hz, 1H), 4.25−4.19 (m, 1H), 4.17−4.08 (m, 3H), 3.62 (s,
3H), 2.77−2.68 (m, 1H), 2.66−2.55 (m, 3H), 2.54−2.48 (m, 1H),
0.89 (d, J = 6.8 Hz, 3H), 0.84 (d, J = 12.2 Hz, 3H). 13C NMR (126
MHz, CDCl3) (major diastereomer) δ 171.2, 170.1, 169.3, 156.3,
144.5, 144.2, 143.9, 141.2, 129.5, 129.4, 129.3, 128.1, 128.0, 127.9,
127.6, 127.0, 126.9, 126.7, 125.1, 119.9, 67.8, 66.9, 66.6, 60.3, 60.2,
59.8, 51.4, 47.0, 33.7, 33.3, 31.3, 19.2, 17.7. HRMS (ESI-TOF) m/z:
[M + H]+ Calcd. for C65H62N3O6S2 1044.4074; Found 1044.4075.
Methyl N-(N-((((9H-Fluoren-9-yl)methoxy)carbonyl)-L-isoleucyl)-
S-tritylcysteinyl)-S-trityl-L-cysteinate, 5i. Yield = 39% (0.41 g), yellow
gum, Rf 0.41 (EtOAc/PE, 30:70), [α]D
25 = +166.9 (C1, CHCl3).
1H
NMR (500 MHz, CDCl3) (major diastereomer) δ 7.87−7.08 (m,
39H), 6.35 (d, J = 7.7 Hz, 1H), 6.17 (d, J = 9.4 Hz, 1H), 4.48−4.40
(m, 1H), 4.39−4.33 (m, 2H), 4.25 (t, J = 6.9 Hz, 1H), 4.18−4.10 (m,
1H), 4.08−3.96 (m, 1H), 3.62 (s, 3H), 2.70−2.65 (m, 2H), 2.64−2.53
(m, 2H), 1.81−1.73 (m, 1H), 1.50−1.33 (m, 2H), 0.96 (d, J = 12.4
Hz, 3H), 0.88 (t, J = 6.4 Hz, 3H). 13C NMR (126 MHz, CDCl3)
(major diastereomer) δ 170.1, 170.0, 169.2, 156.0, 144.2, 143.7, 141.3,
129.5, 129.5, 128.1, 128.0, 127.7, 127.1, 126.9, 125.1, 120.0, 67.2, 66.7,
59.7, 52.5, 51.5, 47.1, 37.0, 33.6, 24.7, 15.5, 11.4. HRMS (ESI-TOF)
m/z: [M + H]+ Calcd. for C66H64N3O6S2 1058.4231; Found
1058.4233.
Methyl N-(N-Benzoyl-N-benzylglycyl)-S-trityl-L-cysteinate Com-
pound, 5J. Yield = 88% (0.55 g), white solid, mp: 97−98 °C, Rf
0.52 (EtOAc/PE, 30:70). 1H NMR (500 MHz, CDCl3) (major
rotamer) δ 7.81−7.20 (m, 25H), 5.82 (br, s, 1H), 4.96−4.90 (m, 1H),
4.73 (s, 2H)), 4.16 (s, 2H), 3.68 (s, 3H), 2.88−2.79 (m, 1H), 2.77−
2.50 (m, 1H). 13C NMR (126 MHz, CDCl3) (major rotamer) δ 170.5,
170.1, 169.1, 144.7, 136.4, 130.6, 129.9, 127.7, 126.8, 126.5, 126.1,
125.7, 67.3, 59.8, 57.1, 52.5, 51.2, 30.3, 29.4. HRMS (ESI-TOF) m/z:
[M + H]+ Calcd. for C39H37N2O4S 629.2468; Found 629.2467.
Methyl N-(N-Benzyl-N-(3-phenylpropanoyl)glycyl)-S-trityl-L-cys-
teinate, 5k. Yield = 91% (0.59 g), white solid, mp: 74−75 °C, Rf
0.35 (EtOAc/PE, 30:70). 1H NMR (500 MHz, CDCl3) (major
rotamer) δ 7.51−7.11 (m, 25H), 6.81 (d, J = 8.8 Hz, 1H), 4.66 (s,
2H), 4.59−4.50 (m, 1H), 4.11 (s, 2H), 3.69 (s, 3H), 3.22−3.88 (m,
2H), 2.68 (t, J = 12.8 Hz, 2H), 2.57 (t, J = 18.6 Hz, 2H). 13C NMR
(126 MHz, CDCl3) (major rotamer) δ 171.1, 170.5, 168.4, 144.2,
140.9, 135.6, 129.7, 129.5, 129.4, 129.0, 128.8, 128.5, 128.1, 127.9,
126.9, 126.2, 66.8, 52.6, 51.9, 51.2, 49.4, 34.9, 33.3, 31.2. HRMS (ESI-
TOF) m/z: [M + H]+ Calcd for C41H41N2O4S 657.2781; Found
657.2784.
Methyl N-(N-(4-Chlorobenzyl)-N-(4-phenylbutanoyl)leucyl)-S-tri-
tyl-L-cysteinate, 5l. Yield = 89% (0.67 g), yellow gum, Rf 0.46
(EtOAc/PE, 30:70), [α]D
25 = +79.4 (C1, CHCl3).
1H NMR (500
MHz, CDCl3) (major diastereomer) δ 7.51−6.83 (m, 25H), 5.24−
5.21 (m, 1H), 4.48 (s, 2H), 4.30−4.25 (m, 1H), 3.69 (s, 3H), 2.80−
2.74 (m, 2H), 2.69−2.50 (m, 2H), 2.20−2.14 (m, 2H), 1.98−1.85 (m,
3H), 1.55−1.48 (m, 1H), 0.92 (d, J = 9.6 Hz, 3H), 0.87 (d, J = 12.8
Hz, 3H). 13C NMR (126 MHz, CDCl3) (major diastereomer) δ 175.5,
170.8, 170.4, 144.2, 141.2, 136.2, 132.9, 129.5, 128.5, 128.4, 128.0,
127.8, 127.2, 126.8, 126.0, 66.9, 55.4, 52.5, 51.2, 47.8, 36.8, 35.0, 32.9,
26.6, 26.5, 25.1, 22.4, 22.3. HRMS (ESI-TOF) m/z: [M + H]+ Calcd.
for C46H50ClN2O4S 761.3174; Found 761.3171.
Methyl N-(((9H-Fluoren-9-yl)methoxy)carbonyl)-L-valylglycyl-S-
trityl-D-cysteinate, 5m. Yield = 51% (0.57 g), yellow gum, Rf 0.32
(EtOAc/PE, 50:50), [α]D
25 = −22.0 (C1, CHCl3). 1H NMR (500
MHz, CDCl3) δ 7.77 (dd, J = 7.7, 3.3 Hz, 2H), 7.59 (dd, J = 13.4, 7.5
Hz, 2H), 7.46−7.35 (m, 5H), 7.35−7.02 (m, 14H), 6.48 (d, J = 8.6
Hz, 1H), 6.30 (d, J = 16.0 Hz, 1H), 5.42 (d, J = 12.2 Hz, 1H), 4.52 (d,
J = 6.4 Hz, 2H), 4.41 (dd, J = 10.6, 7.4 Hz, 1H), 4.31 (d, J = 10.6, 1H),
4.18 (dt, J = 15.8, 7.1 Hz, 1H), 4.09 (br, s, 2H), 3.62 (s, 3H), 2.73 (dd,
J = 12.6, 6.6 Hz, 1H), 2.65 (dd, J = 12.6, 4.9 Hz, 1H), 2.20−2.11 (m,
1H), 0.97 (d, J = 6.8 Hz, 3H), 0.89 (d, J = 12.0 Hz, 3H). 13C NMR
(126 MHz, CDCl3) δ 172.2, 170.6, 168.6, 156.7, 144.2, 143.9, 143.8,
141.3, 129.5, 128.2, 127.8, 127.7, 127.1, 126.9, 125.2, 120.0, 119.9,
67.2, 67.0, 60.5, 52.6, 51.5, 47.1, 42.8, 33.6, 31.1, 19.3, 18.0. HRMS
(ESI-TOF) m/z: [M + H]+ Calcd. for C45H51N3O6S 756.3101; Found
756.3100.
Methyl N-(((9H-Fluoren-9-yl)methoxy)carbonyl)-D-valylglycyl-S-
trityl-L-cysteinate, 5n. Yield = 45% (0.49 g), yellow gum, Rf 0.33
(EtOAc/PE, 50:50), [α]D
25 = −36.4 (C1, CHCl3). 1H NMR (500
MHz, CDCl3) δ 7.78 (d, J = 7.7 Hz, 2H), 7.59 (d, J = 13.5 Hz, 2H),
7.47−7.37 (m, 10H), 7.28−7.17 (m, 9H), 6.88 (d, J = 7.8 Hz, 1H),
6.55 (d, J = 14.2 Hz, 1H), 5.72 (d, J = 8.5 Hz, 1H), 4.51 (d, J = 6.4 Hz,
2H), 4.34 (dd, J = 10.7, 6.9 Hz, 1H), 4.30 (t, J = 7.1 Hz, 1H), 4.17−
4.11 (m, 1H), 4.00 (br, s, 2H), 3.65 (s, 3H), 2.76 (dd, J = 12.5, 6.8 Hz,
1H), 2.67 (dd, J = 9.5, 3.2 Hz, 1H), 2.17−2.10 (m, 1H), 0.96 (d, J =
13.9, 3H), 0.88 (d, J = 6.7 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ
172.0, 170.5, 168.5, 156.6, 144.2, 143.8, 141.2, 129.5, 128.5, 128.2,
127.7, 127.1, 126.9, 126.6, 125.1, 120.0, 67.1, 66.8, 60.5, 52.7, 51.5,
47.2, 42.8, 33.5, 31.0, 19.3, 17.9. HRMS (ESI-TOF) m/z: [M + H]+
Calcd. for C45H52N3O6S 756.3101; Found 756.3100.
Procedure for Entries a−f in Table 2. A solution of Ugi product
5d (1.0 mmol), in 10 mL of CH2Cl2 was maintained at the
temperature indicated in the table. After 5 min, the corresponding
reagents were added slowly. The reaction mixture was allowed to stir
until the starting material was completely consumed (TLC analysis).
The solution was quenched with saturated NaHCO3 and the solution
was extracted with CH2Cl2 (2 × 10 mL), and the organic layer was
separated, dried over MgSO4, ﬁltered, and evaporated. The crude
product in CHCl3 (10 mL) was treated with activated MnO2 (10
mmol), and the reaction mixture was reﬂuxed for 3 h at 80 °C. The
crude reaction mixture was analyzed with SFC-MS.
Procedure for Entries g−i in Table 2. A solution of PPh3O or
Ph2SO (6.0 mmol) in 10 mL of CH2Cl2 was cooled to −78 °C, triﬂic
anhydride (3.0 mmol) was added dropwise and stirred at the same
temperature for 30 min. Pyridine (6.0 mmol) was added to the
reaction mixture. A solution of Cys(Trt) amide (1.0 mmol) in 5 mL of
CH2Cl2 was added and stirred at the indicated temperature in the
table. After complete consumption of the reactant (TLC analysis) the
reaction mixture was warmed to r.t. and quenched with saturated
solution of NaHCO3. The solution was extracted with CH2Cl2 (2 × 10
mL) and the organic layer was separated, dried over MgSO4, ﬁltered,
and evaporated. The crude product in CHCl3 (10 mL) was treated
with activated MnO2 (10 mmol), and the reaction mixture was
reﬂuxed for 3h at 80 °C. The reaction mixture was cooled to r.t. and
ﬁltered through a pad of diatomaceous earth. After evaporation of the
solvent, the residue was puriﬁed by ﬂash chromatography (silica gel,
PE/EtOAc) and gave the corresponding azoles.
General Procedure for the Optimized Synthesis of 1,3-Azoles
6a−c and 6j−l. A solution of diphenyl sulfoxide (3.0 mmol) in 10 mL
of CH2Cl2 cooled to −78 °C, triﬂic anhydride (1.5 mmol) was added
dropwise and stirred at the same temperature for 30 min, and pyridine
(3.0 mmol) was added to the reaction mixture. A solution of Cys(Trt)
amide (1.0 mmol) in 5 mL of CH2Cl2 was added and stirred for 5h at
−78 °C. After complete consumption of the reactant (TLC analysis)
the reaction mixture was warmed to r.t. and quenched with saturated
solution of NaHCO3. The solution was extracted with CH2Cl2 (2 × 10
mL) and the organic layer was separated, dried over MgSO4, ﬁltered,
and evaporated. The crude product in CHCl3 (10 mL) was treated
with activated MnO2 (10 mmol), and the reaction mixture was
reﬂuxed for 3 h at 80 °C. The reaction mixture was cool to r.t. and
ﬁltered through a pad of diatomaceous earth. After evaporation of the
solvent, the residue was puriﬁed by ﬂash chromatography (Silica gel,
PE/EtOAc) and gave the corresponding azoles.
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General Procedure for the Synthesis of 6d−i. A solution of
diphenyl sulfoxide (6.0 mmol) in 15 mL of CH2Cl2 cooled to −78 °C,
triﬂic anhydride (3.5 mmol) was added dropwise and stirred at same
temperature for 30 min. Pyridine (6.0 mmol) was added to the
reaction mixture. A solution of Cys(Trt) amide (1.0 mmol) in 5 mL of
CH2Cl2 was added dropwise, and the reaction mixture was stirred for 6
h at −78 °C. After completion of the reaction (TLC analysis) a
saturated solution of NaHCO3 was added and extracted with CH2Cl2
(2 × 10 mL). The organic layer was separated, dried over MgSO4,
ﬁltered and evaporated. The crude product in CHCl3 (10 mL) was
treated with activated MnO2 (10.0 mmol), and the reaction mixture
was reﬂuxed for 3 h at 80 °C. The reaction mixture was cool to r.t. and
ﬁltered through a pad of diatomaceous earth. After evaporation of the
solvent, the residue was puriﬁed by ﬂash chromatography (Silica gel,
PE/EtOAc) and gave the corresponding azoles.
Methyl (S)-2-((2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-
methylbutanamido)methyl)thiazole-4-carboxylate, 6a. yield = 71%
(0.35 g), white solid, mp: 98−99 °C, Rf 0.51 (EtOAc/PE, 40:60),
[α]D
25 = +7.2 (C1, CHCl3).
1H NMR (500 MHz, CDCl3) δ 8.21 (s,
1H), 7.78−7.11 (m, 8H), 5.80 (d, J = 12.6 Hz, 1H), 5.72 (d, J = 6.0
Hz, 1H), 4.42 (d, J = 8.6 Hz, 2H), 4.23 (t, J = 12.4, 1H), 4.20−4.14
(m, 1H), 4.00 (br, s, 2H), 3.77 (s, 3H), 2.61−2.49 (m, 1H), 0.99 (d, J
= 12.1 Hz, 3H), 0.96 (d, J = 3.8 Hz, 3H). 13C NMR (126 MHz,
CDCl3) δ 169.5, 164.1, 160.2, 156.4, 143.9, 143.7, 141.3, 127.8, 127.1,
126.3, 125.1, 124.3, 123.7, 120.0, 67.1, 65.4, 51.8, 47.2, 37.4, 31.0, 19.1,
17.5. HRMS (ESI-TOF) m/z: [M + H]+ Calcd. for C26H28N3O5S
494.1744; Found 494.1747.
Methyl (S)-2-((2-(((Benzyloxy)carbonyl)amino)propanamido)-
methyl)thiazole-4-carboxylate, 6b. Yield = 80% (0.30 g), white
solid, mp: 75−76 °C, Rf 0.51 (EtOAc/PE, 40:60), [α]D25 = +15.5 (C1,
CHCl3).
1H NMR (500 MHz, CDCl3) δ 8.16 (s, 1H), 7.48−7.15 (m,
5H), 6.28 (d, J = 12.2 Hz, 1H), 5.81 (d, J = 6.8 Hz, 1H), 5.12 (s, 2H),
4.31 (dd, J = 3.4, 12.8 Hz, 1H), 4.15 (d, J = 8.1 Hz, 2H), 3.78 (s, 3H),
1.40 (d, J = 9.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 169.0, 163.7,
160.6, 156.5, 144.2, 136.1, 129.5, 128.5, 128.2, 128.1, 128.0, 126.9,
67.1, 54.1, 52.7, 43.1, 18.4. HRMS (ESI-TOF) m/z: [M + H]+ Calcd.
for C17H20N3O5S 378.1118; found 378.1118.
Methyl 2-(1-(2-(((Benzyloxy)carbonyl)amino)acetamido)-3-
methylbutyl)thiazole-4-carboxylate, 6c. Yield = 65% (0.27 g), yellow
solid, mp: 69−71 °C, Rf 0.43 (EtOAc/PE, 50:50). 1H NMR (500
MHz, CDCl3) δ 8.24 (s, 1H), 7.31−7.49 (m, 5H), 6.73 (d, J = 3.5 Hz,
1H), 6.08 (d, J = 5.6 Hz, 1H), 5.15 (s, 2H), 4.10−4.18 (m, 1H), 3.81
(d, J = 7.6 Hz, 2H), 3.68 (s, 3H), 1.72 (dt, J = 11.6, 5.4, 1.3 Hz, 2H),
1.11−1.25 (m, 1H), 0.92 (d, J = 11.4 Hz, 3H), 0.86 (d, J = 5.7 Hz,
3H). 13C NMR (126 MHz, CDCl3) δ 170.0, 169.3, 160.8, 155.6, 148.6,
136.4, 130.6, 128.1, 127.9, 127.6, 127.0, 126.6, 66.3, 52.5, 50.0, 43.1,
40.4, 24.3, 22.7, 21.1. HRMS (ESI-TOF) m/z: [M + H]+ Calcd. for
C20H26N3O5S 420.1587; Found 420.1583.
Methyl (S)-2-(2-(1-(((Benzyloxy)carbonyl)amino)-2-phenylethyl)-
oxazol-4-yl)thiazole-4-carboxylate, 6d. Yield = 45% (0.20 g), white
solid, mp: 111−112 °C, Rf 0.33 (EtOAc/PE, 60:40), [α]D25 = +13.7
(C1, CHCl3).
1H NMR (500 MHz, CDCl3) δ 8.50 (s, 1H), 7.99 (s,
1H), 7.61−7.32 (m, 1H), 6.91 (br, s, 1H), 5.28 (s, 2H), 5.11−5.03 (m,
1H), 3.79 (s, 3H), 2.65 (dd, J = 15.1, 8.6 Hz, 1H), 2.48 (dd, J = 22.4,
6.5 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 168.2, 167.9, 167.5,
156.9, 145.7, 140.6, 136.0, 135.7, 129.5, 129.4, 128.7, 128.6, 128.5,
128.3, 128.3, 128.2, 128.0, 127.7, 127.2, 123.8, 121.5, 67.8, 54.8, 50.5,
38.6. HRMS (ESI-TOF) m/z: [M + H]+ Calcd. for C24H22N3O5S
464.1274; Found 464.1272.
Methyl (S)-2-(2-(1-(((benzyloxy)carbonyl)amino)ethyl)oxazol-4-
yl)thiazole-4-carboxylate, 6e. Yield = 62% (0.24 g), white solid,
mp: 85−86 °C, Rf 0.33 (EtOAc/PE, 60:40), [α]D25 = +24.6 (C1,
CHCl3).
1H NMR (500 MHz, CDCl3) δ 8.26 (s, 1H), 7.70 (s, 1H),
7.32−7.28 (m, 5H), 6.48 (d, J = 5.8 Hz, 1H), 5.18 (s, 2H), 4.50−4.46
(m, 1H), 3.80 (s, 3H), 1.48 (d, J = 12.6 Hz, 3H). 13C NMR (126
MHz, CDCl3) δ 164.6, 160.8, 159.0, 155.8, 144.9, 141.1, 136.0, 128.6,
128.3, 128.2, 128.0, 122.3, 120.7, 67.6, 53.2, 49.5, 18.4. HRMS (ESI-
TOF) m/z: [M + H]+ Calcd. for C18H18N3O5S 388.0961; Found
388.0965.
Methy l (S ) -2 - (2- (1- ( ( (Benzy loxy )carbony l )amino)-2 -
methylpropyl)oxazol-4-yl)thiazole-4-carboxylate, 6f. Yield = 55%
(0.22 g), white solid, mp: 69−70 °C, Rf 0.33 (EtOAc/PE, 60:40),
[α]D
25 = +32.5 (C1, CHCl3).
1H NMR (500 MHz, CDCl3) δ 8.26 (s,
1H), 7.79 (s, 1H), 7.51−7.20 (m, 5H), 6.23 (br, s, 1H), 5.15 (s, 2H),
4.48 (dd, J = 12.8, 6.5 Hz, 1H), 3.78 (s, 3H), 2.30−2.28 (m, 1H), 1.12
(d, J = 12.5 Hz, 3H), 0.98 (d, J = 5.6 Hz, 3H). 13C NMR (126 MHz,
CDCl3) δ 161.6, 160.7, 159.5, 153.8, 144.8, 140.6, 136.2, 128.6, 128.5,
128.4, 128.2, 128.1, 127.9, 127.1, 123.8, 122.9, 67.2, 63.8, 50.8, 31.1,
19.1, 19.0, 17.4. HRMS (ESI-TOF) m/z: [M + H]+ Calcd. for
C20H22N3O5S 416.1274; Found 416.1272.
Methyl (S)-2′-(1-(((Benzyloxy)carbonyl)amino)-2-phenylethyl)-
[2,4′-bithiazole]-4-carboxylate, 6g. Yield = 49% (0.23 g), pale
yellow gum, Rf 0.33 (EtOAc/PE, 60:40), [α]D
25 = +14.8 (C1, CHCl3).
1H NMR (500 MHz, CDCl3) δ 8.25 (s, 1H), 7.98 (s, 1H), 7.51−7.10
(m, 10H), 5.61 (d, J = 8.4 Hz, 1H), 5.11 (s, 2H), 4.80−4.71 (m, 1H),
3.75 (s, 3H), 3.25 (dd, J = 9.8, 2.5 Hz, 1H), 3.18 (dd, J = 22.4, 18.1
Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 169.3, 163.7, 162.0, 156.3,
146.4, 145.3, 140.0, 136.1, 129.9, 129.7, 129.2, 128.5, 128.3, 128.1,
128.0, 127.0, 126.5, 120.5, 112.7, 67.6, 58.8, 50.6, 37.8. HRMS (ESI-
TOF) m/z: [M + H]+ Calcd. for C24H22N3O4S2 480.1046; Found
480.1046.
Methyl (S)-2′-(1-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-2-
methylpropyl)-[2,4′-bithiazole]-4-carboxylate, 6h. Yield = 64% (0.33
g), white solid, mp: 107−108 °C, Rf 0.25 (EtOAc/PE, 50:50), [α]D25 =
+22.6 (C1, CHCl3).
1H NMR (500 MHz, CDCl3) δ 8.18 (s, 1H), 7.79
(s, 1H), 7.63−7.10 (m, 8H), 6.18 (br, s, 1H), 4.49 (d, J = 4.5 Hz, 2H),
4.48−4.30 (m, 1H), 4.23 (t, J = 11.4 Hz, 1H), 3.80 (s, 3H), 2.32−2.24
(m, 1H), 1.01 (d, J = 8.9 Hz, 3H), 0.98 (d, J = 15.4 Hz, 3H). 13C
NMR (126 MHz, CDCl3) δ 167.8, 163.7, 160.8, 156.4, 149.2, 145.8,
143.9, 143.7, 141.3, 129.7, 127.8, 127.1, 126.1, 125.5, 125.1, 122.8,
120.0, 120.0, 117.0, 67.2, 63.8, 52.5, 47.2, 31.1, 19.1, 17.5. HRMS
(ESI-TOF) m/z: [M + H]+ Calcd. for C27H26N3O4S2 520.1359;
Found 520.1358.
Methyl 2′-((1S,2S)-1-((((9H-Fluoren-9-yl)methoxy)carbonyl)-
amino)-2-methylbutyl)-[2,4′-bithiazole]-4-carboxylate, 6i. yield =
56% (0.29 g), white solid, mp: 114−115 °C, Rf 0.30 (EtOAc/PE,
50:50), [α]D
25 = +7.9 (C1, CHCl3).
1H NMR (500 MHz, CDCl3) δ
8.20 (s, 1H), 7.76 (s, 1H), 7.63−7.02 (m, 8H), 6.28 (d, J = 9.4 Hz,
1H), 4.49 (d, J = 13.5 Hz, 2H), 4.46−4.38 (m, 1H), 4.26 (t, J = 11.1
Hz, 1H), 3.79 (s, 3H), 1.61−1.49 (m, 1H), 1.25 (dt, J = 22.1, 18.5,
11.6 Hz, 2H), 1.01−0.91 (m, 6H). 13C NMR (126 MHz, CDCl3) δ
168.2, 163.7, 160.8, 155.8, 149.8, 148.5, 143.8, 143.7, 141.3, 135.5,
129.4, 128.7, 127.8, 127.3, 127.1, 125.1, 125.0, 123.7, 120.0, 114.5,
67.1, 54.6, 50.5, 47.1, 37.7, 22.9, 14.9, 11.9. HRMS (ESI-TOF) m/z:
[M + H]+ Calcd for C28H28N3O4S2 534.1515; Found 534.1512.
Methyl 2-((N-Benzylbenzamido)methyl)thiazole-4-carboxylate,
6j. Yield = 76% (0.27 g), white solid, mp: 101−102 °C, Rf 0.38
(EtOAc/PE, 50:50). 1H NMR at 38 °C (500 MHz, CDCl3) δ 8.17 (s,
1H), 7.58−7.07 (m, 10H), 4.98 (s, 2H), 4.59 (s, 2H), 3.90 (s, 3H).
13C NMR 1H NMR at 38 °C (126 MHz, CDCl3) δ 172.2, 167.4,
161.4, 145.9, 135.7, 134.9, 130.2, 129.4, 129.3, 128.9, 128.7, 128.6,
128.5, 128.0, 127.8, 127.6, 126.9, 52.9, 52.4, 46.6. HRMS (ESI-TOF)
m/z: [M + H]+ Calcd for C20H19N2O3S 367.1110; Found 367.1115.
Methyl 2-((N-Benzyl-3-phenylpropanamido)methyl)thiazole-4-
carboxylate, 6k. Yield = 73% (0.28 g), white solid, mp: 89−91 °C,
Rf 0.41 (EtOAc/PE, 50:50).
1H NMR (500 MHz, CDCl3) (major
rotamer) δ 8.25 (s, 1H), 7.74−7.05 (m, 10H), 4.85 (s, 2H), 4.53 (s,
2H), 3.81 (s, 3H), 3.11 (t, J = 8.9 Hz, 2H), 2.74 (t, J = 16.8 Hz, 2H).
1H NMR (500 MHz, CDCl3) (minor rotamer) δ 8.21 (s, 0.2 H),
7.74−7.05 (m, 3 H), 4.74 (s, 0.7H), 4.61 (0.5 H), 3.83 (s, 0.8 H),
3.15−3.13 (m, 0.4 H), 2.76−2.74 (m, 0.5H). 13C NMR (126 MHz,
CDCl3) (major rotamer) δ 31.4, 34.7, 47.4, 51.2, 52.4, 126.2, 127.5,
127.8, 127.9, 128.4, 128.8, 129.3, 135.6, 140.1,145.5, 147.4, 161.4,
168.5, 173.3. 13C NMR (126 MHz, CDCl3) (minor rotamer) δ 31.2,
35.0, 48.6, 49.4, 52.5, 126.1, 126.8, 127.5, 128.5, 129.3, 136.4, 140.7,
147.5, 161.5, 169.5, 172.5. HRMS (ESI-TOF) m/z: [M + H]+ Calcd
for C22H23N2O3S 395.1423; Found 395.1424.
Methyl 2-(1-(N-(4-Chlorobenzyl)-4-phenylbutanamido)-3-
methylbutyl)thiazole-4-carboxylate, 6l. Yield = 79% (0.39 g),
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white solid, mp: 121−122 °C, Rf 0.52 (EtOAc/PE, 50:50). 1H NMR
(500 MHz, CDCl3) (maior rotamer) δ 8.10 (s, 1H), 7.45−6.78 (m,
10H), 5.97 (t, J = 7.7 Hz, 1H), 4.53 (s, 2H), 3.92 (s, 3H), 2.62 (t, J =
7.5 Hz, 2H), 2.26 (t, J = 14.8 Hz, 2H), 2.16−1.99 (m, 2H), 1.93−1.85
(m, 2H), 1.55−1.51 (m, 1H), 0.92 (d, J = 6.6 Hz, 3H), 0.88 (d, J = 6.6
Hz, 3H). 13C NMR (126 MHz, CDCl3) (major rotamer) δ 174.0,
169.9, 161.7, 146.1, 141.4, 137.2, 132.9, 129.5, 128.8, 128.5, 128.4,
128.3, 128.1, 127.4, 127.0, 57.6, 52.5, 48.1, 45.8, 40.4, 35.2, 33.1, 26.6,
24.5, 22.4, 22.1. HRMS (ESI-TOF) m/z: [M + H]+ Calcd. for
C27H32ClN2O3S 499.1816; Found 499.1817.
Methyl (S)-2-(((S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)-
amino)-3methyl butanamido) methyl)-4,5-dihydrothiazole-4-car-
boxylate, 7a. Yield = 82% (0.31g), yellow gum, Rf 0.25 (EtOAc/PE,
60:40), [α]D
25 = −98.9 (C1, CHCl3). 1H NMR (500 MHz, CDCl3) δ
7.87−7.11 (m, 8H), 7.03−6.90 (m, 1H), 5.57 (d, J = 8.4 Hz, 1H), 4.84
(dt, J = 8.2, 4.4 Hz, 1H), 4.49−4.33 (m, 2H), 4.27−4.14 (m, 1H),
4.10−3.92 (m, 2H), 3.72 (s, 3H), 2.95 (dd, J = 9.1, 4.5 Hz, 2H), 2.25−
2.07 (m, 1H), 0.94 (dt, J = 26.7, 6.8 Hz, 6H). 13C NMR (126 MHz,
CDCl3) δ 178.1, 176.2, 170.1, 156.6, 143.8, 141.3, 127.8, 127.1, 125.1,
120.0, 74.7, 67.1, 60.7, 52.8, 47.3, 43.5, 35.5, 29.6, 19.3, 18.1. HRMS
(ESI-TOF) m/z: [M + H]+ Calcd. for C26H30N3O5S 496.1900; Found
496.1904.
Methyl (R)-2-(((S)-2-(((Benzyloxy)carbonyl)amino)propanamido)-
methyl)-4,5-dihydrothiazole-4-carboxylate, 7b. Yield = 82% (0.24
g), yellow gum, Rf 0.28 (EtOAc/PE, 60:40), [α]D
25 = +9.8 (C1,
CHCl3)
1H NMR (500 MHz, CDCl3) δ 7.40−7.18 (m, 5H), 5.91 (d, J
= 7.2 Hz, 1H), 5.17 (s, 2H), 5.06 (d, J = 11.7 Hz, 1H), 4.85 (dt, J =
7.8, 4.7 Hz, 1H), 4.32 (d, J = 6.8 Hz, 2H), 3.73 (s, 3H), 3.01−2.90 (m,
2H), 1.39 (d, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 177.0,
176.7, 170.0, 154.1, 136.0, 129.4, 128.5, 128.4, 128.2, 128.1, 74.3, 67.0,
54.0, 51.4, 43.0, 33.5, 18.8, 18.3. HRMS (ESI-TOF) m/z: [M + H]+
Calcd. for C17H22N3O5S 380.1274; Found 380.1271.
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Alexander Dömling: 0000-0002-9923-8873
Notes
The authors declare no competing ﬁnancial interest.
■ ACKNOWLEDGMENTS
The work was ﬁnancially supported from the NIH (NIH
2R01GM097082-05) and by the Innovative Medicines
Initiative (Grant Agreement No. 115489), also European
Union’s Seventh Framework Programme (FP7/2007-2013)
and EFPIA companies’ in-kind contribution and was also
supported by the European Regional Development Fund in the
framework of the Polish Innovation Economy Operational
Program (Contract No. POIG.02.01.00-12-023/08). Funding
has from the European Union’s Horizon 2020 research and
innovation programme under MSC ITN “Accelerated Early
stage drug dIScovery” (AEGIS, Grant Agreement No. 675555)
and CoFund ALERT (Grant Agreement No. 665250).
■ REFERENCES
(1) Burkholz, Ba. L. A. T; Schneider, T.; Jacob, C. The Role of
Cysteine in Amino Acids, Peptides and Proteins in Organic Chemistry;
Hughes, A. B., Ed.; In Amino Acids, Peptides and Proteins in Organic
Chemistry: Analysis and Function of Amino Acids and Peptides; Wiley-
VCH: Weinheim, 2012, Vol. 5; pp 361−394.
(2) (a) Reddie, K. G.; Carroll, K. S. Curr. Opin. Chem. Biol. 2008, 12,
746. (b) Bill, R. M.; Flitsch, S. L. Chem. Biol. 1996, 3, 145.
(3) Kent, S. B. H. Chem. Soc. Rev. 2009, 38, 338.
(4) (a) Pace, N. J.; Weerapana, E. ACS Chem. Biol. 2013, 8, 283.
(b) Chalker, J. M.; Bernardes, G. J. L.; Davis, B. G.; Lin, Y. A. Chem. -
Asian J. 2009, 4, 630.
(5) (a) Dunbar, K. L.; Mitchell, D. A. J. Am. Chem. Soc. 2013, 135,
8692. (b) Burkhart, B. J.; Schwalen, C. J.; Mann, G.; Naismith, J. H.;
Mitchell, D. A. Chem. Rev. 2017, 117, 5389. (c) Roy, R. S.; Gehring, A.
M.; Milne, J. C.; Belshaw, P. J.; Walsh, C. T. Nat. Prod. Rep. 1999, 16,
249.
(6) (a) Wipf, P.; Wang, Z. Org. Lett. 2007, 9, 1605. (b) Nicolaou, K.
C.; Yin, Y.; Mandal, D.; Erande, R. D.; Klahn, P.; Jin, M.; Aujay, M.;
Sandoval, S.; Gavrilyuk, J.; Vourloumis, D. J. Am. Chem. Soc. 2016, 138,
1698.
(7) (a) Riego, E.; Hernandez, D.; Albericio, F.; Alvarez, M. Synthesis
2005, 2005, 1907. (b) Melby, J. O.; Nard, N. J.; Mitchell, D. A. Curr.
Opin. Chem. Biol. 2011, 15, 369.
(8) (a) Wilson, Z. E.; Fenner, S.; Ley, S. V. Angew. Chem., Int. Ed.
2015, 54, 1284. (b) Kalyon, B.; Helaly, S. E.; Scholz, R.; Nachtigall, J.;
Vater, J.; Borriss, R.; Sussmuth, R. D. Org. Lett. 2011, 13, 2996.
(9) (a) Campiani, G.; De Angelis, M.; Armaroli, S.; Fattorusso, C.;
Catalanotti, B.; Ramunno, B. A.; Nacci, V.; Novellino, E.; Grewer, C.;
Ionescu, D.; Rauen, T.; Griffiths, R.; Sinclair, C.; Fumagalli, E.;
Mennini, T. J. Med. Chem. 2001, 44, 2507. (b) White, J. D.; Kim, T. S.;
Nambu, M. J. Am. Chem. Soc. 1997, 119, 103. (c) Wipf, P. Chem. Rev.
1995, 95, 2115. (d) Wipf, P.; Venkatraman, S. Synlett 1997, 1, 1.
(e) Hawkins, C. J.; Lavin, M. F.; Marshall, K. A.; Van den Brenk, A. L.;
Watters, D. J. J. Med. Chem. 1990, 33, 1634.
(10) (a) Murru, S.; Nefzi, A. ACS Comb. Sci. 2014, 16, 39. (b) Liu, Y.;
Sun, X.; Zhang, X.; Liu, J.; Du, Y. Org. Biomol. Chem. 2014, 12, 8453.
(11) Selected examples: (a) Wipf, P.; Miller, C. P. Tetrahedron Lett.
1992, 33, 907. (b) You, S.-L.; Kelly, J. W. J. Org. Chem. 2003, 68, 9506.
(c) North, M.; Pattenden, G. Tetrahedron 1990, 46, 8267. (d) Biron,
E.; Chatterjee, J.; Kessler, H. Org. Lett. 2006, 8, 2417.
(12) (a) Waki, M.; Meienhofer, J. J. Am. Chem. Soc. 1977, 99, 6075.
(b) Endo, A.; Yanagisawa, A.; Tohma, M. A. S.; Kan, T.; Fukuyama,
T.; Abe, M. J. Am. Chem. Soc. 2002, 124, 6552. (c) Pick, R.; Bauer, M.;
Kazmaier, U.; Hebach, C. Synlett 2005, 0757.
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